NEPA for nausea prevention during T-DXd in advanced HER2+ or HER2-low breast cancer
Part of Cancer clinical trials.
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years old or older.
- You must have advanced breast cancer (spread or not removable by surgery) that is HER2-positive or HER2-low.
- You need to be starting your first cycle of T-DXd (trastuzumab deruxtecan) therapy.
- You must be willing to take the anti-nausea medication NEPA as prescribed.
- You should not have had nausea or vomiting in the week before starting T-DXd, and must not have brain or spinal cord lining metastases.
- You must agree to use highly effective birth control (unless you cannot become pregnant) and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
This study is looking at whether a specific medication can help prevent or reduce nausea and vomiting caused by the breast cancer drug T-DXd (trastuzumab deruxtecan). If you are starting T-DXd for the first time, this study might help you manage those side effects.
This trial tests a medicine called IV NEPA (fosnetupitant/palonosetron) to prevent nausea and vomiting in children who are receiving strong chemotherapy. Patients will receive at least one cycle of chemotherapy that is highly likely to cause these side effects.
This study tests whether the medication NEPA (Netupitant and Palonosetron) can prevent nausea and vomiting in people who have had surgery for liver, gallbladder, or pancreatic cancer. It may help those who want to avoid post-surgery sickness.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
Hear when a new Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.